Alectinib: all 52 studies that test it
Page 1 of 1. Open to participants first (16), then studies with results posted, then the rest; newest registration first within each.
- Treatment of Truncated ALK-positive Bone Cancer Using Crizotinib (Xalkori) or Alectinib (Alecensa)Not yet recruitingNCT07560410Phase 1/2
- A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)RecruitingNCT07001384Phase 1
- Minimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCLCNot yet recruitingNCT06709274Not applicable
- Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGSNot yet recruitingNCT06692491Phase 2
- DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive CancersRecruitingNCT05770037Phase 2/3
- Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal CancerRecruitingNCT05725200Phase 2
- DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening ProtocolRecruitingNCT05722886Phase 2/3
- Alectinib Pharmacokinetic in Patients With NSCLCRecruitingNCT05713006Phase 1/2
- Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib BloodlevelsRecruitingNCT05525338Phase 4
- The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer DrugsRecruitingNCT05159245Phase 2
- PLATFORM Study of Precision Medicine for Rare TumorsRecruitingNCT04423185Phase 2
- ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic ProfilingRecruitingNCT04341181Phase 2
- Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic MutationRecruitingNCT04322890Phase 2
- A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)RecruitingNCT04302025Phase 2
- A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.RecruitingNCT04116541Phase 2
- The Drug Rediscovery Protocol (DRUP Trial)RecruitingNCT02925234Phase 2
- A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid TumorsTerminatedNCT04644315Phase 2Results posted
- A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of ResponseCompletedNCT04632992Phase 2Results posted
- Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung CancerTerminatedNCT03737994Phase 2Results posted
- A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary SiteCompletedNCT03498521Phase 2Results posted
- A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung CancerActive, not recruitingNCT03456076Phase 3Results posted
- ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung CancerTerminatedNCT03445000Phase 2Results posted
- A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive CancerCompletedNCT03194893Phase 3Results posted
- A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid CancerTerminatedNCT03131206Phase 1/2Results posted
- A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)CompletedNCT02838420Phase 3Results posted
- Effect of Hepatic Impairment on the Pharmacokinetics of AlectinibCompletedNCT02621047Phase 1Results posted
- Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and CrizotinibCompletedNCT02604342Phase 3Results posted
- Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung CancerTerminatedNCT02521051Phase 1/2Results posted
- My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid TumorsCompletedNCT02091141Phase 2Results posted
- A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer ParticipantsCompletedNCT02075840Phase 3Results posted
- A Study of the Effects of Posaconazole on Alectinib (RO5424802) Pharmacokinetics in Healthy VolunteersCompletedNCT01984229Phase 1Results posted
- A Study of the Effect of Multiple Doses of Rifampin on the Single Dose Pharmacokinetics of RO5424802CompletedNCT01940510Phase 1Results posted
- A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)CompletedNCT01871805Phase 1/2Results posted
- A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib TreatmentCompletedNCT01801111Phase 1/2Results posted
- A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC)CompletedNCT06624059Phase 3
- Alectinib in Combination With Nivolumab in the Treatment of Recurrent or Refractory HCC Patients Guided With Serum RNase1 and Tumor Expression of PD-L1CompletedNCT06354387Phase 1
- SMMART Adaptive Clinical Treatment (ACT) TrialWithdrawnNCT05238831Early Phase 1
- A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingNCT05170204Phase 3
- Brazilian Lung Immunotherapy StudyCompletedNCT05081674Phase 2
- Alectinib in Neo-adjuvant Treatment of Stage III NSCLCActive, not recruitingNCT05015010Phase 2
- A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS TumorsActive, not recruitingNCT04774718Phase 1/2
- The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and ImmunotherapyActive, not recruitingNCT04591431Phase 2
- Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform StudyActive, not recruitingNCT04589845Phase 2
- CRAFT: The NCT-PMO-1602 Phase II TrialCompletedNCT04551521Phase 2
- Alectinib in Combination With Bevacizumab in ALK Positive NSCLCCompletedNCT03779191Phase 2
- A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLCActive, not recruitingNCT03202940Phase 1/2
- A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingNCT03178552Phase 2/3
- NCT Neuro Master Match - N²M² (NOA-20)CompletedNCT03158389Phase 1/2
- A Study of the Efficacy and Safety of Alectinib in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung CancerCompletedNCT03155009Phase 2
- Deciphering Antitumour Response and Resistance With INtratumour HeterogeneityCompletedNCT02314481Phase 2
- A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC)CompletedNCT02013219Phase 1
- A Study of the Elimination, Pharmacokinetics, and Metabolism of RO5424802CompletedNCT01981005Phase 1